Proactive Investors - Run By Investors For Investors

LeanLife closes first round of financing: raises $750,000

The company said the funds will be used for used for general working capital
LeanLife closes first round of financing: raises $750,000
LeanLife Health's products are extracted from flax seeds, a plentiful and non-animal source of omega-3

Nutritional additive and ingredients group LeanLife Health Inc. (CSE:LLP) announced Thursday it has closed its first round of funding, raising $750,000. 

The company said funds will be used for used for general working capital.

The offering consisted of 15 million units at a price of C$0.05 for total gross proceeds of $750,000. 

READ: LeanLife Health poised for production at new plant once permits are in place

Each unit will consist of one share and one transferable share purchase warrant, which is exercisable into one further share at a price of C$0.075 per share for three years from closing.

LeanLife delivers high concentration levels of omega-3 as a nutritional additive. Its products are for use in commercial food processing.

Last month, it updated on its manufacturing capability, revealing that the main equipment had been purchased and delivered to the new facility in Canada. 

The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.

Such products will include ingredients for making and/or fortifying commercial foods such as bread, noodles, juices, yogurt and cheese.

View full LLP profile View Profile

LeanLife Health Timeline

Newswire
February 07 2019

Related Articles

young girl with allergy
March 22 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use